Carlos S. Moreno, Ph.D.

Assistant Professor Department of Pathology & Laboratory Medicine Emory University School of Medicine Department of Hematology & Medical Oncology Member, Winship Cancer Institute MORENO LAB HOMEPAGE Co-Director, Emory Biomarker Service Center Member, Center for Comprehensive Informatics

RESEARCH INTERESTS:

My laboratory is using DNA microarrays to identify novel targets for cancer therapy in patient tissues from prostate, brain, and ovarian cancers. We are also using model cell culture systems with defined sets of oncogenes to attempt to understand the changes in gene expression that are essential for tumor formation. We are also developing novel bioinformatics techniques to integrate microarray and genomic data and identify functional cis-regulatory DNA elements. Finally, we are using feedback control systems modeling approaches to build new tools for understanding gene transcription regulatory networks.

EDUCATION:

Emory University              Atlanta, GA
                     Ph.D. in Genetics and Molecular Biology (1992-98)

Massachusetts Institute Of Technology                       Cambridge, MA
                     M.S. in Aerospace Engineering (1986-88)

Massachusetts Institute Of Technology                       Cambridge, MA
                     B.S. in Aerospace Engineering (1982-86)

POSTGRADUATE TRAINING:

1998-2001  Postdoctoral Fellow in the laboratory of Dr. David C. Pallas, Biochemistry Department, Emory University School of Medicine.  Identified and analyzed the striatin/SG2NA family of regulatory subunits for Protein Phosphatase 2A (PP2A) and their role in cell cycle regulation.  Discovered that the mouse homolog of MOB1, a yeast protein essential for initiation of cytokinesis and maintenance of ploidy, binds to striatin/PP2A and SG2NA/PP2A complexes and is a PP2A substrate.  Developed and applied quality threshold clustering algorithms for analysis of gene expression profiles of renal carcinomas.

GRADUATE TRAINING:

1992-1998  Studied the regulation of transcription of human Major Histocompatibility Complex (MHC) class II genes.  Cloned and characterized factors that bind to the X box of MHC class II promoters.  One of these factors, X2BP, was purified and shown to be identical to the cAMP response element binding protein (CREB).  The other factor, RFX, was shown to be a multimeric phosphoprotein, and a novel subunit (RFX-B) was identified by metabolic labeling and immunoprecipitation analysis.

RESEARCH EXPERIENCE:

1990-1992 Aerospace Engineer, CS Draper Laboratory, Cambridge, MA.  Developed changes to the Space Shuttle Navigation Flight Software for incorporation of Global Positioning System (GPS) navigation data.   Enhanced and developed computer simulations of Space Shuttle Re-Entry.

1988-1990 Aerospace Engineer, NASA Jet Propulsion Laboratory, Pasadena, CA. Performed technology development research for the Mars Rover/Pathfinder Mission.  Researched remote sample acquisition, robotic end effector technology, semi-autonomous navigation systems, and lander/rover vehicle design.

GRANTS:

NIH National Cancer Institute R01 (2009-14) "2R01 CA106826 Developmental Transcription Factors in Prostate Cancer"

Winship Cancer Institute Seed Grant Award (2008)        "The Role of MicroRNAs in Breast Cancers of Young Women with a Triple Negative Phenotype in Diverse Ethnic Populations"

Winship Cancer Institute Seed Grant Award (2008)        "Identification of Biomarkers Predictive of Clinical Outcome in Prostate Cancer"

PUBLICATIONS:

2009. CS Moreno. The SOX4 and HOXC6 Transcriptional Networks in Prostate Cancer Progression: Crosstalk with the Wnt, Notch, and PI3K Pathways, American Journal of Pathology, in press

2009. T Narita, S Yin, CF Gelin, CS Moreno, KC Nicolaou, and EG Van Meir. Identification of a novel small molecule HIF-1α translation inhibitor, Clinical Cancer Research, 15(19):6128-36.    Journal PubMed

2009. CD Scharer, CD McCabe, M Ali-Seyed, MF Berger, ML Bulyk, and CS Moreno. Genome-wide Promoter Analysis of the SOX4 Transcriptional Network in Prostate Cancer Cells, Cancer Research, 69:709-717.    Journal PubMed

2008. CD Scharer, N Laycock, AO Osunkoya, S Logani, JF McDonald, BB Benigno, and CS Moreno. Aurora Kinase Inhibitors Synergize with Paclitaxel to Induce Apoptosis in Ovarian Cancer Cells. Journal of Translational Medicine, 6:79. PDF Journal PubMed

2008. JS Rao, S Karanam, CD McCabe, and CS Moreno. Genomic Promoter Analysis Predicts Functional Transcription Factor Binding, Advances in Bioinformatics, vol. 2008, Article ID 369830, doi:10.1155/2008/369830. PDF Suppl Data Journal

2008. L Guo, D Zhong, S Lau, X Liu, X Dong, X Sun, P Liu, VW Yang, PM Vertino, CS Moreno, V Varma, J Dong, and W Zhou. SOX7 as an Independent Checkpoint for beta-Catenin Function in Prostate and Colon Epithelial Cells, Molecular Cancer Research, 6(9):1421-1430.    PubMed

2008. CD McCabe, DD Spyropoulos, WD Martin, and CS Moreno. Genome-wide Analysis of the Homeobox C6 Transcriptional Network in Prostate Cancer, Cancer Research, 68(6): 1988-96. PDF Suppl Data PubMed

2008. CO Evans, CS Moreno, X Zhan, M McCabe, PM Vertino, DM Desiderio, and NM Oyesiku. Molecular Signaling in Human Prolactin-Secreting Adenomas Identified by Gene Expression Profiling, RT-qPCR, and Proteomic Analyses, Pituitary, 11(3): 231-45. PDF PubMed

2008. M. Abramovitz, M. Ordanic-Kodani, Y. Wang, Z. Li, C. Catzavelos, M. Bouzyk, G. W. Sledge Jr, C.S. Moreno, and B. Leyland-Jones. Optimization of RNA extraction from FFPE tissues for expression profiling in the DASL assay. Biotechniques, 44(3): 417-23. PDF PubMed

2007. C.S. Moreno, L. Matyunina, E. Dickerson, N. Schubert, N.J. Bowen, S. Logani, B.B. Benigno and J.F. McDonald, Evidence that p53-mediated cell-cycle-arrest inhibits chemotherapeutic treatment of ovarian carcinomas, PLoS ONE, 2(5): e441. PDF PubMed

2007. DL Jaye, N Fujita, CM Geigerman, RE Fuller, S Li, S Hunter, P Taysavang, CS Moreno, and PA Wade. The BCL-6-associated transcriptional corepressor, MTA3, is selectively expressed in germinal center B cells and lymphomas of putative germinal center derivation, Journal of Pathology, 213(1):106-15. PDF PubMed

2006. P. Liu, S. Ramachandran, M. Ali-Seyed, C.D. Scharer, N. Laycock, W. B. Dalton, H. Williams, S. Karanam, M. W. Datta, D. L. Jaye, and C. S. Moreno. SOX4 is a Transforming Oncogene in Human Prostate Cancer Cells. Cancer Research, 66(8):4011-4018. PDF PubMed

2006. Ali-Seyed M, Laycock N, Karanam S, Xiao W, Blair ET, and C. S. Moreno. Cross-Platform Expression Profiling Demonstrates that SV40 Small Tumor Antigen Activates Notch, Hedgehog, and Wnt Signaling in Human Cells. BMC Cancer, 6:54. PDF PubMed

2005. C. S. Moreno, C.O. Evans, X. Zhan, M. Okor, D. M. Desiderio, and N.M. Oyesiku, Novel Molecular Signaling in Human Clinically Non-functional Pituitary Adenomas Identified by Gene Expression Profiling and Proteomic Analyses, Cancer Research, 65(22):10214-10222.    PubMed

2005. A. Schuetz, M. B. Amin, C. S. Moreno, Q. Yin-Goen, C. Cohen, C. D. Hornsby, J. A. Petros, M. M. Issa, J. G. Pattaras, K. Ogan, F. F. Marshall and A. N. Young. Molecular Classification of Renal Tumors by Gene Expression Profiling. Journal of Molecular Diagnostics, 7(2):206-18. PDF PubMed

2005. S. Ramachandran, P. Liu, A. N. Young, Q. Yin-Goen, S. D. Lim, N. Laycock, M. B. Amin, J. K. Carney, F. F. Marshall, J. A. Petros and C. S. Moreno. Loss of HOXC6 Expression Induces Apoptosis in Prostate Cancer Cells. Oncogene, 24(1): 188-198. PDF PubMed

2004. C. S. Moreno, S. Ramachandran, D. Ashby, N. Laycock, C. A. Plattner, W. Chen, W. C. Hahn and D. C. Pallas. Signaling and Transcriptional Changes Critical for Transformation of Human Cells by SV40 Small Tumor Antigen or PP2A B56gamma Knockdown. Cancer Res, 64: 6978-6988. PDF PubMed

2004. S. Karanam and C. S. Moreno. CONFAC: Automated Application of Comparative Genomic Promoter Analysis to DNA Microarray Datasets. Nucleic Acids Res, 32: W475-84. PDF PubMed

2003. N. Fujita, D. L. Jaye, M. Kajita, C. Geigerman, C. S. Moreno and P. A. Wade. MTA3, a Mi-2/NuRD Complex Subunit, Regulates an Invasive Growth Pathway in Breast Cancer. Cell, 113: 207-19. PDF PubMed

2002. S. B. Hunter and C. S. Moreno. Expression microarray analysis of brain tumors: what have we learned so far. Front Biosci, 7: c74-82. PDF PubMed

2001. X. X. Yu, X. Du, C. S. Moreno, R. E. Green, E. Ogris, Q. Feng, L. Chou, M. J. McQuoid and D. C. Pallas. Methylation of the Protein Phosphatase 2A Catalytic Subunit Is Essential for Association of Balpha Regulatory Subunit But Not SG2NA, Striatin, or Polyomavirus Middle Tumor Antigen. Mol Biol Cell, 12: 185-99.    PubMed

2001. A. N. Young, M. B. Amin, C. S. Moreno, S. D. Lim, C. Cohen, J. A. Petros, F. F. Marshall and A. S. Neish. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol, 158: 1639-51.    PubMed

2001. H. Wei, D. G. Ashby, C. S. Moreno, E. Ogris, F. M. Yeong, A. H. Corbett and D. C. Pallas. Carboxymethylation of the PP2A catalytic subunit in Saccharomyces cerevisiae is required for efficient interaction with the B-type subunits Cdc55p and Rts1p. J Biol Chem, 276: 1570-7.    PubMed

2001. C. S. Moreno, W. S. Lane and D. C. Pallas. A mammalian homolog of yeast mob1 is both a member and a putative substrate of striatin family-protein phosphatase 2a complexes. J Biol Chem, 276: 24253-60.    PubMed

2000. C. S. Moreno, S. Park, K. Nelson, D. Ashby, F. Hubalek, W. S. Lane and D. C. Pallas. WD40 repeat proteins striatin and S/G(2) nuclear autoantigen are members of a novel family of calmodulin-binding proteins that associate with protein phosphatase 2A. J Biol Chem, 275: 5257-63.    PubMed

1999. C. S. Moreno, G. W. Beresford, P. Louis-Plence, A. C. Morris and J. M. Boss. CREB regulates MHC class II expression in a CIITA-dependent manner. Immunity, 10: 143-51.    PubMed

1997. C. S. Moreno, E. M. Rogers, J. A. Brown and J. M. Boss. Regulatory factor X, a bare lymphocyte syndrome transcription factor, is a multimeric phosphoprotein complex. J Immunol, 158: 5841-8.    PubMed

1997. P. Louis-Plence, C. S. Moreno and J. M. Boss. Formation of a regulatory factor X/X2 box-binding protein/nuclear factor-Y multiprotein complex on the conserved regulatory regions of HLA class II genes. J Immunol, 159: 3899-909.    PubMed

1995. C. S. Moreno, P. Emery, J. E. West, B. Durand, W. Reith, B. Mach and J. M. Boss. Purified X2 binding protein (X2BP) cooperatively binds the class II MHC X box region in the presence of purified RFX, the X box factor deficient in the bare lymphocyte syndrome. J Immunol, 155: 4313-21.    PubMed

1994. K. C. Chin, C. Mao, C. Skinner, J. L. Riley, K. L. Wright, C. S. Moreno, G. R. Stark, J. M. Boss and J. P. Ting. Molecular analysis of G1B and G3A IFN gamma mutants reveals that defects in CIITA or RFX result in defective class II MHC and Ii gene induction. Immunity, 1: 687-97.    PubMed

MORENO LAB HOMEPAGE

ADDRESS:	Department of Pathology & Laboratory Medicine Emory University School of Medicine Whitehead Research Building, Room 105J 615 Michael St. Atlanta, GA 30322	PHONE:	404-712-2809 (office) 404-712-2808 (lab)
email:	cmoreno@emory.edu	FAX:	404-727-8538